美国食品和药物管理局批准Sequana Medical的alfapump®,这是首款用于肝硬化患者的设备. Sequana Medical gains FDA approval for alfapump®, a first-of-its-kind device for liver cirrhosis patients.

Sequana Medical 的 alfapump® 设备已获得 FDA 批准，这是第一款用于治疗肝硬化腹水的有源植入式设备。 Sequana Medical has received FDA approval for its alfapump® device, the first active implantable device for treating ascites due to liver cirrhosis. 该装置不断从腹部取出液体,改善患者的生活质量。 The device continuously removes fluid from the abdomen, improving patients' quality of life. 据估计,2025年市场规模将超过20亿美元,Sequana计划在2025年下半年在美国的肝移植中心推出alfapump. With an estimated market of over $2 billion in 2025, Sequana plans to launch the alfapump in the US liver transplant centers in the second half of 2025.